SCHEMBL373422

SCHEMBL373422

Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 1.00
MAPK14 Q16539 3/20 1.00
ACVR1B P36896 3/20 1.00
RIPK2 O43353 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
MTOR P42345 1/20 0.63
MAPK13 O15264 1/20 0.45
MAPK12 P53778 1/20 0.45
MAPK11 Q15759 1/20 0.45
KDM4E B2RXH2 1/20 0.43
PRKD3 O94806 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
TGFBR2 P37173 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358831 1.00 TGFBR1 (1.00) TGFBR1MAPK14ACVR1BRIPK2TDP1
SCHEMBL29378125 1.00 TGFBR1 (1.00) TGFBR1MAPK14ACVR1BRIPK2TDP1
Water SCHEMBL21459280 0.99 TGFBR1 (0.98) TGFBR1MAPK14ACVR1BRIPK2TDP1
Hydrochloric Acid SCHEMBL29541686 0.99 TGFBR1 (1.00) TGFBR1MAPK14ACVR1BRIPK2TDP1
Hydrochloric Acid SCHEMBL140197 0.99 TGFBR1 (1.00) TGFBR1MAPK14ACVR1BRIPK2TDP1
Hydrochloric Acid SCHEMBL29361019 0.98 TGFBR1 (0.98) TGFBR1MAPK14ACVR1BRIPK2TDP1
Hydrochloric Acid SCHEMBL14778775 0.98 TGFBR1 (0.98) TGFBR1MAPK14ACVR1BRIPK2TDP1
Hypochlorous Acid SCHEMBL26968133 0.96 TGFBR1 (0.92) TGFBR1MAPK14ACVR1BRIPK2TDP1
SCHEMBL4969183 0.91 TGFBR1 (0.84) TGFBR1MAPK14ACVR1BRIPK2TDP1
SCHEMBL6759987 0.85 TGFBR1 (0.74) TGFBR1MAPK14ACVR1BRIPK2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 EP claimed
US-12371664-B2 Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby CHA BIOTECH CO., LTD. (KR) 2025-07-29 US claimed
CN-118355110-A Method for producing cartilage and bone 默多克儿童研究所 2024-07-16 CN claimed
EP-3384007-B1 IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) 2024-03-27 EP claimed
US-20230364153-A1 METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION Research & Business Foundation Sungkyunkwan University (KR) 2023-11-16 US claimed
CN-115838719-B Compound capable of specifically promoting activity of adenine base editor, chemical regulation method and application thereof 上海交通大学医学院 2023-10-31 CN claimed
WO-2023060322-A1 METHODS FOR PRODUCING CARTILAGE AND BONES MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) 2023-04-20 WO claimed
US-20220186183-A1 NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME Cellapeutics Bio (KR) 2022-06-16 US claimed
US-20220106564-A1 COMPOSITION AND KIT FOR DIFFERENTIATION OF STEM CELLS INTO NEURAL CREST STEM CELLS, INCLUDING INHIBITOR OF TGF-BETA I RECEPTOR AND BMP INHIBITOR, AND METHOD USING SAME CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-04-07 US claimed
WO-2022065859-A1 METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION 성균관대학교산학협력단 2022-03-31 WO claimed
EP-3060649-A1 REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) 2016-08-31 EP claimed
EP-3043822-A1 COMPOSITIONS FOR PREPARING CARDIOMYOCYTES The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) 2016-07-20 EP claimed
US-20160186141-A1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad 2016-06-30 US claimed
WO-2016090408-A1 COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF CELLS NORTHERN SYDNEY LOCAL HEALTH DISTRICT (AU) 2016-06-16 WO claimed
WO-2016029267-A1 A METHOD FOR CULTURING MESENCHYMAL STEM CELLS PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH TRADING AS THE HUDSON INSTITUTE OF MEDICAL RESEARCH (AU) 2016-03-03 WO claimed
WO-2015087231-A1 METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS PFIZER LIMITED (GB) 2015-06-18 WO claimed
US-20150159134-A1 METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS PFIZER LIMITED (GB) 2015-06-11 US claimed
WO-2015061568-A1 REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) 2015-04-30 WO claimed
WO-2015038704-A1 COMPOSITIONS FOR PREPARING CARDIOMYOCYTES THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) 2015-03-19 WO claimed
US-20040220230-A1 Pyridinylimidazoles SMITHKLINE BEECHAM P.L.C. 2004-11-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220186183-A1 NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME GMFG, HGF, BDNF TGFBR1 2424/4885MAPK14 2736/4885ACVR1B 2868/4885
US-20150159134-A1 METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS ALDH1A2, ALDH1A3, EYA3 TGFBR1 4643/4885MAPK14 4549/4885ACVR1B 3755/4885
US-20160186141-A1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES MYLK2, TNNI3, TNNT2 TGFBR1 3113/4885MAPK14 1708/4885ACVR1B 607/4885
US-20040220230-A1 Pyridinylimidazoles NR0B1, NR1I2, NR0B2 TGFBR1 485/4885MAPK14 3471/4885ACVR1B 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.